Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRL-301 in Refractory Systemic Lupus Erythematosus
NCT05988216Recruiting
- Sponsor
- BRL Medicine Inc.
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of BRL-301 in systemic lupus erythematosus (SLE), sponsored by BRL Medicine Inc. Primary endpoint: Safety of BRL-301 at 3 months. Started Aug 2023; status: recruiting.
02
Drugs
BRL-301
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05988216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05988216.